Parthenolide accelerates diabetic wound healing through the STAT3 and TNF-α/NF-kappaB pathways

Area of Science:

• Pharmacology
• Molecular Biology
• Wound Healing Research

Background:

• Diabetic wounds present complex inflammatory challenges and tissue damage.
• Parthenolide (PTL), from Tanacetum balsamita, exhibits anti-inflammatory and antioxidant properties.
• Understanding PTL's mechanism in diabetic wound healing is crucial.

Purpose of the Study:

• To elucidate the molecular mechanisms of Parthenolide (PTL) in promoting diabetic wound healing.
• To identify key molecular targets and signaling pathways involved in PTL's therapeutic effects.
• To evaluate the efficacy of PTL in preclinical diabetic wound models.

Main Methods:

• Network pharmacology and molecular docking to identify PTL targets (TNF-α, STAT3).
• In vivo studies using diabetic mouse models to assess wound repair efficacy.
• In vitro assays (CCK-8, immunofluorescence, Western blotting) on LPS-stimulated macrophages.

Main Results:

• PTL demonstrated a dose-dependent acceleration of wound repair in diabetic mice (100 µM and 200 µM effective).
• PTL enhanced keratinocyte proliferation, angiogenesis, and M2 macrophage polarization.
• PTL modulated STAT3 and TNF-α/NF-κB signaling pathways and macrophage phenotype switching.

Conclusions:

• PTL promotes diabetic wound healing via STAT3 and TNF-α/NF-κB pathway regulation.
• PTL facilitates M2 macrophage polarization, modulating the inflammatory microenvironment.
• PTL shows potential as a therapeutic agent for diabetic wound complications.